Skip to main content

Table 3 Dose-dependent percentage of non-transfected cell viability after treatment with different concentrations of puromycin for up to 6 days

From: CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation

Puromycin concentration

Non-transfected cell viability %

0 μg/mL

100

3 μg/mL

100

6 μg/mL

85

9 μg/mL

30

12 μg/mL

0

15 μg/mL

0